Novotech expands its Asia-Pacific reach with acquisition of Clinical Network Services

asia pacific globe
Novotech expands its Asia-Pacific reach with the acquisition of Clinical Network Services. (blackred iStock)

Novotech continues to expand its reach in the Asia-Pacific region with the acquisition of Australian specialist CRO Clinical Network Services.

Financial terms of the deal weren’t disclosed. The two companies will retain their separate brands and identities.

Clinical Network Services targets small, mid-sized and virtual biotechs with its early phase services. Novotech has more than 400 employees operating in the Asia-Pacific region, including business development staff in the U.S.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Clinical Network Services has a staff of 140 people in Australia, New Zealand and the U.S.

“Biopharma clients should know this is a bringing together of the highest quality CROs in the region,” John Moller, Novotech’s chief executive, said in a statement. “Novotech and CNS will continue to operate under separate brands with CNS specializing in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specializing in regional Asia-Pacific and global project delivery across all phases.”

Novotech has been busy of late. Earlier this month it inked a deal with Bangkok’s Phramongkutklao under which the two will partner to conduct early phase studies at the hospital’s research center while Novotech provides feasibility assessments and recruits patients for studies. In July, the Australian CRO announced a partnership with Philippines-based ophthalmology firm Asian Eye Institute for clinical research.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.